

Company Number: 264010

Goode & Co. (Pharmacy) Limited
Abridged Unaudited Financial Statements
for the financial year ended 30 April 2025

Goode & Co. (Pharmacy) Limited
CONTENTS

	Page
Directors' Responsibilities Statement	3
Accountants' Report	4
Balance Sheet	5
Reconciliation of Shareholders' Funds	6
Notes to the Financial Statements	7 - 12

Goode & Co. (Pharmacy) Limited

DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 30 April 2025

The directors made the following statement in respect of the unaudited financial statements:

"General responsibilities

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Directors' declaration on unaudited financial statements

In relation to the financial statements which comprise the Balance Sheet, the Reconciliation of Shareholders' Funds and the related notes:

The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.

The directors confirm that they have made available to Somers Browne & Associates Limited, (Chartered Accountants), all the company's accounting records and provided all the information, books and documents necessary for the compilation of the financial statements.

The directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the financial year ended 30 April 2025."

Signed on behalf of the board

David Goode
Director

14 January 2026

Joanne Goode
Director

14 January 2026

Goode & Co. (Pharmacy) Limited
CHARTERED ACCOUNTANTS REPORT
to the Board of Directors on the Compilation of the unaudited Abridged financial
statements of Goode & Co. (Pharmacy) Limited
for the financial year ended 30 April 2025

In accordance with the engagement letter and in order to assist you to fulfil your duties under the Companies Act 2014, we have compiled for your approval the abridged financial statements of the company for the financial year ended 30 April 2025 as set out on pages 5 to 12 which comprise the Balance Sheet, the Reconciliation of Shareholders' Funds and the related notes from the company's accounting records and information and explanations you have given to us.

As a practising member firm of the Institute of Chartered Accountants Ireland, we are subject to its ethical and other professional requirements which are detailed at <https://www.charteredaccountants.ie/Professional-Standards/Home>

This report is made solely to the Board of Directors of Goode & Co. (Pharmacy) Limited, as a body, in accordance with the terms of our engagement. Our work has been undertaken so that we might compile the financial statements that we have been engaged to compile, report to the company's Board of Directors that we have done so, and state those matters that we have agreed to state to them in this report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and its Board of Directors, as a body, for our work or for this report.

We have carried out this engagement in accordance with guidance issued by the Institute of Chartered Accountants in Ireland and have complied with the relevant ethical guidance laid down by the Institute of Chartered Accountants in Ireland relating to members undertaking the compilation of financial statements.

You have acknowledged on the Balance Sheet for the year ended 30 April 2025 your duty to ensure that Goode & Co. (Pharmacy) Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Goode & Co. (Pharmacy) Limited. You consider that Goode & Co. (Pharmacy) Limited is exempt from the statutory audit requirement for the financial year.

We have not been instructed to carry out an audit or a review of the abridged financial statements of Goode & Co. (Pharmacy) Limited. For this reason, we have not verified the adequacy, accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory abridged financial statements.

Shane Somers
for and on behalf of
SOMERS BROWNE & ASSOCIATES LIMITED
Chartered Accountants
6th Floor, Riverpoint
Lower Mallow Street
Limerick

14 January 2026

Goode & Co. (Pharmacy) Limited**BALANCE SHEET**

as at 30 April 2025

	Notes	2025 €	2024 €
Fixed Assets			
Tangible assets	8	1,437,131	1,523,435
Investments	9	2,257,460	2,806,626
Fixed Assets		3,694,591	4,330,061
Current Assets			
Stocks	10	196,632	204,356
Debtors	11	316,240	303,315
Cash and cash equivalents		667,098	874,858
		1,179,970	1,382,529
Creditors: amounts falling due within one year	12	(249,694)	(242,063)
Net Current Assets		930,276	1,140,466
Total Assets less Current Liabilities		4,624,867	5,470,527
Provisions for liabilities	13	(28,799)	(77,757)
Net Assets		4,596,068	5,392,770
Capital and Reserves			
Called up share capital presented as equity		200	200
Retained earnings	15	4,595,868	5,392,570
Equity attributable to owners of the company		4,596,068	5,392,770

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

We as Directors of Goode & Co. (Pharmacy) Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 14 January 2026 and signed on its behalf by:

David Goode
Director

Joanne Goode
Director

Goode & Co. (Pharmacy) Limited
RECONCILIATION OF SHAREHOLDERS' FUNDS

as at 30 April 2025

	Called up share capital €	Retained earnings €	Total €
At 1 May 2023	200	5,136,553	5,136,753
Profit for the financial year	-	256,017	256,017
At 30 April 2024	200	5,392,570	5,392,770
Loss for the financial year	-	(796,702)	(796,702)
At 30 April 2025	200	4,595,868	4,596,068

Goode & Co. (Pharmacy) Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

1. General Information

Goode & Co. (Pharmacy) Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 264010. The registered office of the company is 6th Floor, Riverpoint, Lower Mallow Street, Limerick. The principal activity of the company is that of a pharmacy retail outlet. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the financial year ended 30 April 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. Cost comprises purchase price and other directly attributable costs. Freehold land is stated at cost and is not depreciated. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Land and buildings freehold	-	2% straight line
Fixtures, fittings and equipment	-	12.5% straight line
Motor vehicles	-	12.5% straight line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Investment properties

Investment property is property held either to earn rental income, or for capital appreciation (including future re-development) or for both, but not for sale in the ordinary course of business.

Investment property is initially measured at cost, which includes the purchase cost and any directly attributable expenditure. Investment property is subsequently valued at its fair value at each reporting date, by professional external valuers. The difference between the fair value of an investment property at the reporting date and its carrying value prior to the valuation is recognised in the Profit and Loss Account as a fair value gain or loss. Any gain or loss on disposal of an investment property (calculated as the difference between the net proceeds from disposal and the carrying amount of the item) is recognised in the Profit and Loss Account.

Investments

Investments held as fixed assets are stated at cost less provision for any permanent diminution in value. Income from other investments together with any related withholding tax is recognised in the Profit and Loss Account in the financial year in which it is receivable.

Goode & Co. (Pharmacy) Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 30 April 2025

Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. In the Balance Sheet bank overdrafts are shown within Creditors.

Borrowing costs

Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

Provisions

Provisions are recognised when the company has a present legal or constructive obligation arising as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation and a reliable estimate can be made. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the same value of money and the risks specific to the obligation. The increase in the provision due to passage of time is recognised as interest expense.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

Government grants

Capital grants received and receivable are treated as deferred income and amortised to the Profit and Loss Account annually over the useful economic life of the asset to which it relates. Revenue grants are credited to the Profit and Loss Account when received.

Pensions

The company operates a defined contribution pension scheme for employees. The assets of the scheme are held separately from those of the company. Annual contributions payable to the company's pension scheme are charged to the Profit and Loss Account in the period to which they relate.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

Goode & Co. (Pharmacy) Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 30 April 2025

3. Significant accounting judgements and key sources of estimation uncertainty

The preparation of financial statements in conformity with FRS 102 requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making judgements about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision only affects that period or in the period of the revision and future periods if the revision affects both current and future periods.

Going Concern:

In evaluating the company's ability to continue as a going concern, management has exercised judgement regarding future cash flow projections, including assumptions about future trading performance and the availability of financing facilities.

Useful Lives of Fixed Assets:

The company estimates the useful lives of property, plant, and equipment based on the period over which the assets are expected to be available for use. These estimates are reviewed annually and updated if expectations differ from previous estimates due to physical wear and tear or technical obsolescence.

Impairment of Assets:

The company assesses whether there are any indicators of impairment for assets at each reporting date. This involves estimating the recoverable amount of the asset or cash-generating unit, which requires assumptions about future cash flows and appropriate discount rates.

4. Operating (loss)/profit	2025	2024
	€	€
Operating (loss)/profit is stated after charging/(crediting):		
Depreciation of tangible assets	100,235	99,401
(Profit)/loss on disposal of tangible assets	-	4,334
Government grants received	(12,092)	-
	<u> </u>	<u> </u>
5. Income from investments	2025	2024
	€	€
Profit on disposal of investments	28,699	13,529
	<u> </u>	<u> </u>
6. Other Gains and Losses	2025	2024
	€	€
Fair value gains and losses are as follows:		
Investments in shares	(148,357)	200,239
	<u> </u>	<u> </u>

7. Employees

The average monthly number of employees, including directors, during the financial year was 12, (2024 - 12).

Goode & Co. (Pharmacy) Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 30 April 2025

8. Tangible assets

	Land and buildings freehold €	Investment properties €	Fixtures, fittings and equipment €	Motor vehicles €	Total €
Cost					
At 1 May 2024	797,785	605,192	593,927	77,612	2,074,516
Additions	-	1,810	12,121	-	13,931
At 30 April 2025	<u>797,785</u>	<u>607,002</u>	<u>606,048</u>	<u>77,612</u>	<u>2,088,447</u>
Depreciation					
At 1 May 2024	105,856	83,751	351,772	9,702	551,081
Charge for the financial year	15,956	17,102	57,475	9,702	100,235
At 30 April 2025	<u>121,812</u>	<u>100,853</u>	<u>409,247</u>	<u>19,404</u>	<u>651,316</u>
Net book value					
At 30 April 2025	<u>675,973</u>	<u>506,149</u>	<u>196,801</u>	<u>58,208</u>	<u>1,437,131</u>
At 30 April 2024	<u>691,929</u>	<u>521,441</u>	<u>242,155</u>	<u>67,910</u>	<u>1,523,435</u>

9. Investments

	Listed investments €	Other unlisted investments €	Total €
Investments			
Cost or Valuation			
At 1 May 2024	1,459,325	1,347,301	2,806,626
Additions	180,893	64,057	244,950
Disposals	(545,758)	(100,000)	(645,758)
Revaluations	(12,800)	(135,558)	(148,358)
At 30 April 2025	<u>1,081,660</u>	<u>1,175,800</u>	<u>2,257,460</u>
Net book value			
At 30 April 2025	<u>1,081,660</u>	<u>1,175,800</u>	<u>2,257,460</u>
At 30 April 2024	<u>1,459,325</u>	<u>1,347,301</u>	<u>2,806,626</u>

10. Stocks

	2025 €	2024 €
Goods for resale	<u>196,632</u>	<u>204,356</u>

The replacement cost of stock did not differ significantly from the figures shown.

11. Debtors

	2025 €	2024 €
Trade debtors	141,178	131,846
Other debtors	121,922	113,813
Directors' current accounts (Note 17)	-	36,716
Taxation	38,439	19,059
Prepayments	14,701	1,881
	<u>316,240</u>	<u>303,315</u>

Goode & Co. (Pharmacy) Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

12. Creditors	2025	2024
Amounts falling due within one year	€	€
Amounts owed to credit institutions	88	2,125
Trade creditors	167,128	127,879
Taxation	66,583	104,469
Directors' current accounts (Note 17)	8,305	-
Accruals	7,590	7,590
	<u>249,694</u>	<u>242,063</u>

The repayment terms of trade creditors vary between on demand and ninety days. No interest is payable on trade creditors.

Tax and social insurance are subject to the terms of the relevant legislation. Interest accrues on late payment at the rate of 0.0219% for corporation tax per day and 0.0274% for VAT and PAYE per day. No interest was due at the financial year end date.

The terms of the accruals are based on underlying contracts. Other amounts included within creditors not covered by specific note disclosures are unsecured, interest free and repayable on demand.

13. Provisions for liabilities

The amounts provided for deferred taxation are analysed below:

	Other differences	Total
	2025	2024
	€	€
At financial year start	77,757	8,847
Charged to profit and loss	(48,958)	68,910
At financial year end	<u>28,799</u>	<u>77,757</u>

14. Pension costs - defined contribution

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. Pension costs amounted to €672,000 (2024 - €51,600).

15. Income Statement

	2025	2024
	€	€
At 1 May 2024	5,392,570	5,136,553
(Loss)/profit for the financial year	(796,702)	256,017
At 30 April 2025	<u>4,595,868</u>	<u>5,392,570</u>

16. Capital commitments

The company had no material capital commitments at the financial year-ended 30 April 2025.

Goode & Co. (Pharmacy) Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 30 April 2025

17. Directors' remuneration and transactions	2025	2024
	€	€
Directors' remuneration		
Remuneration	730,654	386,658
Pension contributions	672,000	51,600
	<u>1,402,654</u>	<u>438,258</u>

18. Related party transactions

There were no related party transactions during the year.

19. Controlling interest

The key controlling parties in Goode & Co. (Pharmacy) Limited are David Goode and Joanne Goode.

20. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

21. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 14 January 2026.